Tiotropium/Formoterol — Competitive Intelligence Brief

Tiotropium/Formoterol (Tiotropium/Formoterol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory/Pulmonology.

marketed Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (tiotropium); Beta-2 adrenergic receptor (formoterol) Respiratory/Pulmonology Small molecule

Target snapshot

Tiotropium/Formoterol (Tiotropium/Formoterol) — Neutec Ar-Ge San ve Tic A.Ş. Tiotropium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while formoterol is a long-acting beta-2 agonist that stimulates bronchodilation, together providing sustained airway opening for chronic obstructive pulmonary disease.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tiotropium/Formoterol TARGET	Tiotropium/Formoterol	Neutec Ar-Ge San ve Tic A.Ş	marketed	Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (tiotropium); Beta-2 adrenergic receptor (formoterol)
Aclidinium bromide/formoterol fumarate combination	Aclidinium bromide/formoterol fumarate combination	AstraZeneca	marketed	Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor and beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) class)

1. AstraZeneca · 1 drug in this class
2. Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class